NCT05269316View on ClinicalTrials.gov

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Solid TumorAdvanced Solid Tumor
Interventions
DRUG

IMP9064

IMP9064 Monotherapy administered for 21 days

Trial Locations (8)

2148

COMPLETED

Blacktown Hospital, Blacktown

6009

COMPLETED

Linear Clinical Research Limited, Nedlands

10002

COMPLETED

National Taiwan University Hospital, Taipei

10029

COMPLETED

Mount Sinai, New York

29605

COMPLETED

Greenville Hospital System University Medical Center (ITOR), Greenville

75251

COMPLETED

Mary Crowley Cancer Research Centers, Dallas

100142

RECRUITING

Beijing Cancer Hospital, Beijing

07601

COMPLETED

Hackensack University Medical Center PARTNER, Hackensack

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT05269316 - Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter